-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

Benzinga·01/05/2026 13:36:02
語音播報
D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.